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 Abstract 
 
Introduction: Tardive dyskinesia is one of the major side effects of long-term neuroleptic 
treatment. Increased reactive oxygen species and oxidative stress has been proposed as possible 
etiopathologic mechanisms. Ginkgo biloba extract (EGB) is a natural antioxidant. We investigated 
the effects of ginkgo biloba extract on neuroleptic-induced orofacial dyskinesia in rats, a potential 
animal model for tardive dyskinesia. 
Methods: Orofacial dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i.p) 
for a period of 21 days. On 22nd day, animals were assessed for development of oral dyskinesia. 
Malon di aldehyde (MDA), glutathione (GSH), superoxide dismutase (SOD) and catalase levels 
were evaluated in animal forebrain homogenate. 
Results: Chronic haloperidol (1 mg/kg) treatment significantly increased the vacuous chewing 
movement’s frequency, increased MDA and decreased SOD and catalase levels. Co-administration 
of EGB 25 mg/kg along with haloperidol suppressed the haloperidol induced vacuous chewing 
movements (Pvalue < 0.05). EGB 100 mg/kg reversed haloperidol induced reduction in SOD level. 
It also reversed the increment in MDA level observed in haloperidol treated rats. 
Conclusion: The present study suggested that oxidative stress plays a significant role in 
neuroleptic-induced orofacial dyskinesia and EGB co-administration reverses these behavioral and 
biochemical changes. 
Declaration Interest: None. 
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     Introduction  
      Tardive dyskinesia (TD) is one of the major 
side effects of long-term neuroleptic treatment. 
Neuroleptics are extensively used in the treatment 
of schizophrenia and other affective disorders. 
TD, which occurs in 20–40% of patients taking 
chronic neuroleptic medication, is a major 
limitation of neuroleptic therapy (1-4). Oxidative 
stress and products of lipid peroxidation are 
implicated in the pathophysiology of various 
neurological disorders (5). A role for increased 
reactive  oxygen species  and  oxidative  stress  in  
 
 
the etiopathology of neuroleptic-induced TD has 
been proposed (6-8). Chronic treatment with 
neuroleptics increases free radical production and 
oxidative stress (9) and also forebrain 
malondialdehyde (MDA) level, as a marker of 
lipid peroxidation (10). Additionally, Elkashef et 
al. (11)
 
have reported that rats with vacuous 
chewing movement had significantly higher 
thiobarbituric acid reactive substances (TBARS) 
in the striatum, suggesting increased lipid 
peroxidation and free radical production in these 
animals. 
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Chronic use of neuroleptics is also reported to 
cause decrease in the activity of antioxidant 
defense enzymes, superoxide dismutase (SOD) 
and catalase (6, 12). Free radicals are thought to 
play a role in the aging process, and age is one of 
the risk factors for the development of TD. 
Richardson et al. (13) had reported a positive 
correlation between increasing age and the 
development of TD, further supporting the role of 
free radicals in the pathogenesis of TD. Vitamin 
E, an antioxidant and free radical scavenger has 
been reported to be effective in the treatment of 
TD (5, 11, 14-16). All these observations strongly 
support the role of free radicals in TD. 
Ginkgo biloba extract (EGB), a natural antioxidant, 
is an extract from green leaves of the Ginkgo 
biloba tree. The main ingredients of EGB are 
ginkgo-flavone glycosides (24%) and terpenoids 
(6%). It is well known for its cheap prices and 
negligible side effects. EGB has various biological 
activities and different pharmacologic effects, 
including antioxidation, anti-inflammatory and 
modulation of immune response. For its few side 
effects, EGB is extensively used in the therapy of 
central neural system disorders, acute pancreatitis, 
myocardial, and intestinal ischemia/reperfusion 
injury which are associated with inflammatory 
mediators(17-20). It has also been reported that 
EGB could scavenge oxidative-free radicals and  
down-regulate some of the inflammatory mediators 
involved in inflammatory responses, including 
TNF-α and IL-6(21). 
In the present study we investigated the effects of 
ginkgo biloba extract on neuroleptic-induced 
orofacial dyskinesia in rats, a potential animal 
model for tardive dyskinesia. 
 
    Methods 
     Male Sprague-Dawley rats (250-300 g) were 
used in this study. The animals were housed 
under standard laboratory conditions, maintained 
on a 12-h light and dark cycle and had access to 
food and water ad libitum. Animals were 
acclimatized to the laboratory conditions prior to 
experimentation. All the experiments were 
carried out between 09:00 a.m. and 15:00 p.m. 
The experimental protocols were approved by the 
Institutional Animal Ethics Committee and 
conducted according to the International 
Guidelines for the use and care of experimental 
animals. 
Haloperidol (1 mg/kg i.p) was administered 
chronically to rats for a period of 21 days to 
induce oral dyskinesia (22, 23). All the behavioral 
assessments were carried out after 24 h of the last 
dose of haloperidol (22
nd
 day). 
On the test day (22nd) rats were placed individually 
in a small (30 × 20 × 30 cm) Plexiglas cage for 
the assessment of oral dyskinesia.  Animals were 
allowed 10 minutes to get used to the observation 
cage before behavioral assessments. Tongue 
protrusion and vacuous chewing movements 
(frequencies) were counted with the help of a 
hand operated counter by trained observers. 
Vacuous chewing movements (VCM) are referred 
to as single mouth openings in the vertical plane 
not directed toward a physical object. If tongue 
protrusion and vacuous chewing movements 
occurred during a period of grooming, they were 
not taken into account. Counting was stopped 
whenever the rat began grooming, and restarted 
when grooming was over. Orofacial dyskinesia 
(tongue protrusions and VCMs) was measured 
continuously for a period of 5 min. In all the 
experiments the scorer was unaware of the 
treatment given to the animals. 
On the 22
nd
 day of haloperidol treatment, the 
animals were sacrificed by decapitation 
immediately after behavioral assessment. The 
brains were removed, forebrain was dissected out 
and rinsed with isotonic saline and weighed. A 
10% (w/v) tissue homogenate was prepared in 0.1 
M phosphate buffer (pH 7.4). The post nuclear 
fraction for catalase assay was obtained by 
centrifugation of the homogenate at 1000 × g for 
20 min, at 4 °C and for other enzyme assays 
centrifuged at 12,000 × g for 60 min. at 4 °C. 
 
The quantitative measurement of lipid peroxidation 
in forebrain was performed using Colorimetric kit 
(TBARS Assay Kit- Cayman Chemical, Michigan, 
USA). The dynamic range of the kit was 0-50µM 
MDA. Intra-assay coefficient of variation was 
5.5%. 
Reduced glutathione in the forebrain tissue was 
estimated using Colorimetric kit (Glutathione 
Assay Kit- Cayman Chemical, Michigan, USA). 
The dynamic range of the kit was 0-16µM GSH 
(or 0-8 µM GSSG). Intra-assay coefficient of 
variation was 1.6%. 
Superoxide dismutase activity was assayed using 
Colorimetric kit (Superoxide Dismutase Assay 
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Kit- Cayman Chemical, Michigan, USA). The 
dynamic range of the kit was 0.025-0.25 units/ml 
SOD. Intra-assay coefficient of variation was 
3.2%. 
Catalase activity was assayed using Colorimetric 
kit Catalase Assay Kit- Cayman Chemical, 
Michigan, USA). The dynamic range of the kit is 
limited only by the accuracy of the absorbance 
measurement. Intra-assay coefficient of variation 
was 3.8%. 
The following drugs were used in the present 
study. Haloperidol (IPDIC co., Iran) was diluted 
with distilled water. Ginkgo biloba extract 
(Goldaroo co., Iran) was suspended in vehicle (2% 
tween solution 80°). All drugs were administered 
intraperitoneally in a constant volume of 0.5 ml 
per 100 g of body weight of rat. Animals were 
divided into the following groups. Vehicle: 
saline; vehicle: haloperidol; haloperidol: EGB (25 
mg/kg); haloperidol: EGB (50 mg/kg); haloperidol: 
EGB (100 mg/kg) groups respectively. Haloperidol 
was administered once daily (1.5 mg/Kg) in the 
morning (9 am) and this group also received 
vehicle for EGB twice daily. EGB was given 
once daily (9 am) for a period of 21 days and 
behavioral assessments were measured 24 h after 
the last dose. Drug doses were selected on the 
basis of previous studies reported in the literature 
(3, 23- 24). 
Statistical data analysis 
One specific group of rats was assigned to one 
specific drug treatment condition and each group 
comprised six rats (n=6). All the values are 
expressed as means ± S.E.M. The data were 
analyzed by using analysis of variance (ANOVA) 
followed by Tukey’s test. In all tests, the criterion 
for statistical significance was P<0.05. 
 
    Results 
    Effect of Ginkgo biloba extract on haloperidol-
induced vacuous chewing movements and tongue 
protrusions 
Chronic haloperidol (1mg/kg) treatment 
significantly increased the vacuous chewing 
movements (VCMs) frequency but did not have a 
statistically significant effect on tongue protrusion 
frequency when compared with vehicle treated 
controls. Chronic co-administration of EGB 25 
mg/kg along with haloperidol suppressed the 
haloperidol induced vacuous chewing movements 
(Pvalue<0.05). Other dosages of EGB (50 and 
100 mg/Kg) did not change VCM or tongue 
protrusion frequencies significantly in comparison 
with the control group (Fig. 1, 2). 
Effect of Ginkgo biloba extract on the forebrain 
MDA level in chronic haloperidol treated rats 
Chronic administration of haloperidol for 21 days 
induced lipid peroxidation as indicated by a rise 
in forebrain MDA level compared with vehicle 
treated rats(P value<0.05). Coad ministration of 
EGB (100 mg/ Kg) along with haloperidol 
significantly reversed the extent of lipid 
peroxidation as compared to haloperidol only 
treated rats( P value<0.01). Other doses of EGB 
(25 and 50 mg/Kg) did not have a significant 
effect on forebrain MDA levels compared with 
the control group (fig. 3). 
Effect of Ginkgo biloba extract on the forebrain 
glutathione (GSH) levels in chronic haloperidol 
treated rats Statistical analysis of forebrain GSH 
levels did not show a significant difference 
between vehicle-treated and haloperidol treated 
rats. Co-administration of EGB (25– 100 mg/kg) 
for 21 days did not change GSH levels compared 
to haloperidol only treated animals (fig. 4). 
Effect of Ginkgo biloba extract on the forebrain 
antioxidant enzyme levels in chronic haloperidol 
treated rats. Chronic haloperidol treatment 
reduced levels of forebrain antioxidant enzyme 
SOD significantly compared with control group 
(P value<0.01). Co-administration of EGB 100 
mg/kg along with haloperidol significantly 
increased SOD level compared with haloperidol 
only treated group(P value<0.05). Other doses of 
EGB (25 & 50 mg/kg) failed to reverse 
haloperidol induced reduction of forebrain SOD 
(Fig 5).  
Chronic haloperidol treated rats showed 
decreased levels of catalase in their forebrain 
homogenates (P value<0.001). Various doses of 
EGB (25-50 mg/kg) co administered with 
haloperidol did not affect forebrain catalase levels 
significantly (Fig 6). 
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*: P value<0.05 compared with control group 
॥ :P value<0.05 compared with haloperidol only treated group 
 
Figure 1. Effect of Ginkgo biloba extract on haloperidol-
induced vacuous chewing movements (VCM) 
 
 
 
 
 
 
Figure 2. Effect of Ginkgo biloba extract on haloperidol-
induced tongue protrusions 
 
 
 
 
 
*: P value <0.05 compared with control group. 
**: P value <0.01 compared with haloperidol only treated group. 
 
 
 
Figure 3. Effect of Ginkgo biloba extract on the forebrain 
MDA level in chronic haloperidol treated rats 
 
 
 
 
 
Figure 4. Effect of Ginkgo biloba extract on the forebrain 
glutathione (GSH) levels in chronic haloperidol treated rats 
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*: P value <0.05 compared with haloperidol only treated group. 
**: P value <0.01 compared with control group. 
 
Figure 5. Effect of Ginkgo biloba extract on the forebrain 
SOD level in chronic haloperidol treated rats. 
 
 
 
 
***: P value < 0.001 compared with the control group. 
 
Figure 6. Effect of Ginkgo biloba extract on the forebrain 
Catalase level in chronic haloperidol treated rats. 
 
     Conclusion 
      Existing evidences indicate that production of 
free radicals is associated with chronic neuroleptic 
use and this might contribute to the onset of 
tardive dyskinesia and other movement disorders, 
such as dystonias and Parkinsonism (6, 16). This 
effect can be related, at least in part, to a 
reduction in specific endogenous antioxidant 
mechanisms, such as a decrease in GSH levels 
(25) and low levels of antioxidant defense 
enzymes such as SOD and catalase respectively 
(11). Neuroleptics act by blocking dopamine 
receptors (26).
 
Such blockade results in increased 
dopamine turnover (27), which in turn could 
conceivably lead to an increased production of 
hydrogen peroxide, resulting in oxidative stress 
(11, 28). However, this does not seem to be the 
only mechanism responsible for the GSH 
depletion observed during haloperidol treatment 
(29). Another possibility is that neuroleptics 
suppress the activity of certain detoxifying 
enzymes, leaving cells unprotected especially if 
basal enzyme activity is low or the free radical-
scavenging mechanisms are less effective. Free 
radicals are highly reactive with specific cellular 
components and have cytotoxic properties (30), 
and neuronal loss in the striatum has been 
reported in animals treated chronically with 
neuroleptics (31). 
In this study, chronic haloperidol treated animals 
showed increased forebrain MDA level and 
vacuous chewing movements and decreased SOD 
and catalase activity. These results correspond 
with earlier studies further supporting the role of 
lipid peroxidation and production of free radicals 
in neuroleptic induced TD (6, 11). 
EGB was shown to have a dose dependent 
beneficial effect in the TNBS (trinitrobenzene 
sulfonic acid) induced colitis in rats (21). As a 
possible mechanism, Yan-Hong Zhou et al. (21) 
suggested that EGB can scavenge oxidative-free 
radicals and down-regulate some of the 
inflammatory mediators involved in the intestinal 
immune and inflammatory responses, including 
TNF-α, NF κBp65 and IL-6 resulting in the 
improvement of ulcerative colitis (21). 
Additionally, Bridi et al. demonstrated that EGB 
could increase the antioxidant enzyme catalase 
and SOD activities in the hippocampus, striatum 
and substantia nigra in rats and decrease lipid 
peroxidation in the hippocampus (32). 
Furthermore, Chao et al. suggested that Ginkgo 
biloba extract can increase PGE2 level, SOD 
activity, and reduce oxidative damage by the 
actions of cytoprotection and antioxidation to 
improve the repair of the duodenal mucosa in 
duodenal ulcer rats (33). 
EGB pretreatment was shown to ameliorate 
ethanol-induced damage in rat live. It was 
suggested that heme oxygenase-1 up-regulation 
by EGB was involved in the prophylactic effect 
(34).
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Pattipati et al. (35) demonstrated that administration 
of quercetin (an active ingredient of EGB) dose 
dependently reduced lipid peroxidation and 
restored the decreased glutathione levels in 
haloperidol-treated animals. Quercetin (50–100 
mg/ kg) was also shown to reverse the 
haloperidol - induced decrease in forebrain SOD 
and catalase levels in rats. 
In this study, EGB (100mg/kg) co-administration 
along with haloperidol reversed the haloperidol 
induced increase in forebrain MDA level, and 
restored SOD depletion. Furthermore, EGB 25 
mg/kg significantly reduced VCM in haloperidol-
treated animals. These results, though not dose 
dependent, further support the positive anti-
oxidant properties of EGB. Accordingly, one or 
several of these actions of EGB may contribute to 
the reversal of haloperidol-induced oxidative 
injury and orofacial dyskinesia. 
In conclusion, the present study confirms that 
oxidative stress plays a significant role in 
neuroleptic - induced orofacial dyskinesia. 
Moreover, it demonstrates that chronic EGB 
treatment reverses the haloperidol induced 
increase in the frequency of orofacial dyskinesia, 
as well as haloperidol-induced increase in brain 
lipid peroxidation. EGB also reverses the effect 
of haloperidol in reduction of forebrain SOD 
level. These results further strengthen the 
oxidative stress hypothesis of tardive dyskinesia 
(36-38) and suggest a beneficial clinical use of 
EGB in preventing this motor disorder. 
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